Browsing: NICE

Pharming’s Joenja, a treatment for APDS, has been approved for reimbursement in England after NICE reversed its earlier rejection. The EU regulatory review is still ongoing.

A former senior figure at England’s NICE states that advanced therapies for common conditions would not qualify for the usual payment modifiers.

Understand how NICE prioritizes key topic areas for evaluation and what this means for innovators in the healthtech sector.

Understand how NICE prioritizes health technology evaluations and what it means for innovators.

A new consultation from the National Institute for Health and Care Excellence (NICE) marks a significant step towards incorporating quantitative assessments of health inequalities in its health technology appraisals, prompting a re-evaluation of how new technologies are evaluated.